Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Diabetes & Metabolism Year : 2008

Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis.

Abstract

Prevalence of non-alcoholic steatohepatitis (NASH) rises steadily in Western countries with the obesity epidemic. NASH is associated with activation of liver fibrogenesis and predisposes to cirrhosis and associated morbi-mortality. The cannabinoid system is increasingly emerging as a crucial mediator of acute and chronic liver injury. Recent experimental and clinical data indicate that peripheral activation of cannabinoid CB1 receptors promotes insulin resistance and liver steatogenesis, two key steps in the pathogenesis of non-alcoholic fatty liver disease. Moreover, CB1 receptors enhance progression of liver fibrogenesis. These findings provide a strong rationale for the use of CB1 antagonists in the management of NASH.
Fichier principal
Vignette du fichier
inserm-00371854_edited.pdf (72.45 Ko) Télécharger le fichier
Diabetes_and_metbolism_Cannabinoids_AND_NASH_2008_A_Mallat.pdf (41.72 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00371854 , version 1 (30-03-2009)

Identifiers

Cite

Ariane Mallat, Sophie Lotersztajn. Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis.. Diabetes & Metabolism, 2008, 34 (6 Pt 2), pp.680-4. ⟨10.1016/S1262-3636(08)74604-4⟩. ⟨inserm-00371854⟩

Collections

INSERM IMRB UPEC
246 View
697 Download

Altmetric

Share

Gmail Facebook X LinkedIn More